OKYO

Okyo Pharma (OKYO)

Okyo Pharma Limited

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:OKYO

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	20 : 00	UK Regulatory	OKYO Pharma Announces Participation in May 2024 Investor Conferences	LSE:OKYO	Okyo Pharma Limited
2024/04/30	20 : 00	UK Regulatory	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	LSE:OKYO	Okyo Pharma Limited
2024/04/09	08 : 00	UK Regulatory	OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024	LSE:OKYO	Okyo Pharma Limited
2024/04/02	20 : 00	UK Regulatory	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery	LSE:OKYO	Okyo Pharma Limited
2024/03/22	20 : 00	UK Regulatory	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	LSE:OKYO	Okyo Pharma Limited
2024/03/21	20 : 00	UK Regulatory	OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	LSE:OKYO	Okyo Pharma Limited
2024/03/20	20 : 00	UK Regulatory	OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event	LSE:OKYO	Okyo Pharma Limited
2024/02/09	21 : 36	InvestorsHub NewsWire	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
2024/02/09	21 : 00	UK Regulatory	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
2024/01/31	21 : 00	UK Regulatory	OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board	LSE:OKYO	Okyo Pharma Limited
2023/05/22	16 : 15	UK Regulatory	OKYO Pharma Limited London Stock Exchange Delisting	LSE:OKYO	Okyo Pharma Limited
2023/05/22	16 : 00	UK Regulatory	London Stock Exchange Notice Cancellation - OKYO PHARMA LIMITED	LSE:OKYO	Okyo Pharma Limited
2023/05/19	19 : 22	Alliance News	IN BRIEF: Okyo Pharma to move shares to New York with London delisting	LSE:OKYO	Okyo Pharma Limited
2023/05/19	16 : 00	RNS Non-Regulatory	OKYO Pharma Limited ADS Program collapse	LSE:OKYO	Okyo Pharma Limited
2023/05/15	15 : 00	UK Regulatory	OKYO Pharma Limited Change of Record Time and Last Day of Dealings	LSE:OKYO	Okyo Pharma Limited
2023/05/11	22 : 27	Alliance News	IN BRIEF: Okyo Pharma delays delisting from London trading to May 22	LSE:OKYO	Okyo Pharma Limited
2023/05/11	20 : 00	RNS Non-Regulatory	OKYO Pharma Limited Webull Corporate Communications Service Platform	LSE:OKYO	Okyo Pharma Limited
2023/05/11	15 : 00	UK Regulatory	OKYO Pharma Limited Change of Delisting Date to 22 May 2023	LSE:OKYO	Okyo Pharma Limited
2023/05/03	21 : 00	UK Regulatory	OKYO Pharma Limited Result of Meeting	LSE:OKYO	Okyo Pharma Limited
2023/05/03	15 : 00	RNS Non-Regulatory	OKYO Pharma Limited Presentation on OK-101 at ASCRS	LSE:OKYO	Okyo Pharma Limited
2023/05/03	04 : 16	Alliance News	TRADING UPDATES: Knights Group buys St James Law and Baines Wilson	LSE:OKYO	Okyo Pharma Limited
2023/05/02	15 : 00	UK Regulatory	OKYO Pharma Limited First-Patient First-Visit for Phase 2 Trial	LSE:OKYO	Okyo Pharma Limited
2023/04/26	00 : 19	Alliance News	TRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facility	LSE:OKYO	Okyo Pharma Limited
2023/04/25	15 : 00	UK Regulatory	OKYO Pharma Limited Activation of First Clinical Trial Site in the U.S	LSE:OKYO	Okyo Pharma Limited
2023/04/05	15 : 00	UK Regulatory	OKYO Pharma Limited NOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATION	LSE:OKYO	Okyo Pharma Limited
2023/04/04	17 : 08	Alliance News	Okyo Pharma applies to delist from London Stock Exchange due to costs	LSE:OKYO	Okyo Pharma Limited
2023/04/04	15 : 00	UK Regulatory	OKYO Pharma Limited Notice Of Intention To Delist From The LSE	LSE:OKYO	Okyo Pharma Limited
2023/03/30	15 : 00	UK Regulatory	OKYO Pharma Limited Director Acquires Shares	LSE:OKYO	Okyo Pharma Limited
2023/03/29	15 : 00	UK Regulatory	OKYO Pharma Limited Director acquires shares	LSE:OKYO	Okyo Pharma Limited
2023/03/24	16 : 00	UK Regulatory	OKYO Pharma Limited Director/PDMR Shareholding	LSE:OKYO	Okyo Pharma Limited